On Jan. 31, 2022, Veru announced that the U.S. Food and Drug Administration (FDA) had granted Fast Track designation to the Phase 3 registration program for the investigation of sabizabulin, a novel, proprietary, oral cytoskeleton disruptor with both anti-viral and anti-inflammatory properties, to combat COVID-19 infection and the cytokine storm that is responsible for Acute Respiratory Distress Syndrome and death.